Cargando…

A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine

A successful severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine must not only be safe and protective, but must also meet the demand on a global scale at a low cost. Using the current influenza virus vaccine production capacity to manufacture an egg-based inactivated Newcastle disea...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Weina, McCroskery, Stephen, Liu, Wen-Chun, Leist, Sarah R., Liu, Yonghong, Albrecht, Randy A., Slamanig, Stefan, Oliva, Justine, Amanat, Fatima, Schäfer, Alexandra, Dinnon, Kenneth H., Innis, Bruce L., García-Sastre, Adolfo, Krammer, Florian, Baric, Ralph S., Palese, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7766959/
https://www.ncbi.nlm.nih.gov/pubmed/33348607
http://dx.doi.org/10.3390/vaccines8040771
_version_ 1783628843620237312
author Sun, Weina
McCroskery, Stephen
Liu, Wen-Chun
Leist, Sarah R.
Liu, Yonghong
Albrecht, Randy A.
Slamanig, Stefan
Oliva, Justine
Amanat, Fatima
Schäfer, Alexandra
Dinnon, Kenneth H.
Innis, Bruce L.
García-Sastre, Adolfo
Krammer, Florian
Baric, Ralph S.
Palese, Peter
author_facet Sun, Weina
McCroskery, Stephen
Liu, Wen-Chun
Leist, Sarah R.
Liu, Yonghong
Albrecht, Randy A.
Slamanig, Stefan
Oliva, Justine
Amanat, Fatima
Schäfer, Alexandra
Dinnon, Kenneth H.
Innis, Bruce L.
García-Sastre, Adolfo
Krammer, Florian
Baric, Ralph S.
Palese, Peter
author_sort Sun, Weina
collection PubMed
description A successful severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine must not only be safe and protective, but must also meet the demand on a global scale at a low cost. Using the current influenza virus vaccine production capacity to manufacture an egg-based inactivated Newcastle disease virus (NDV)/SARS-CoV-2 vaccine would meet that challenge. Here, we report pre-clinical evaluations of an inactivated NDV chimera stably expressing the membrane-anchored form of the spike (NDV-S) as a potent coronavirus disease 2019 (COVID-19) vaccine in mice and hamsters. The inactivated NDV-S vaccine was immunogenic, inducing strong binding and/or neutralizing antibodies in both animal models. More importantly, the inactivated NDV-S vaccine protected animals from SARS-CoV-2 infections. In the presence of an adjuvant, antigen-sparing could be achieved, which would further reduce the cost while maintaining the protective efficacy of the vaccine.
format Online
Article
Text
id pubmed-7766959
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77669592020-12-28 A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine Sun, Weina McCroskery, Stephen Liu, Wen-Chun Leist, Sarah R. Liu, Yonghong Albrecht, Randy A. Slamanig, Stefan Oliva, Justine Amanat, Fatima Schäfer, Alexandra Dinnon, Kenneth H. Innis, Bruce L. García-Sastre, Adolfo Krammer, Florian Baric, Ralph S. Palese, Peter Vaccines (Basel) Article A successful severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine must not only be safe and protective, but must also meet the demand on a global scale at a low cost. Using the current influenza virus vaccine production capacity to manufacture an egg-based inactivated Newcastle disease virus (NDV)/SARS-CoV-2 vaccine would meet that challenge. Here, we report pre-clinical evaluations of an inactivated NDV chimera stably expressing the membrane-anchored form of the spike (NDV-S) as a potent coronavirus disease 2019 (COVID-19) vaccine in mice and hamsters. The inactivated NDV-S vaccine was immunogenic, inducing strong binding and/or neutralizing antibodies in both animal models. More importantly, the inactivated NDV-S vaccine protected animals from SARS-CoV-2 infections. In the presence of an adjuvant, antigen-sparing could be achieved, which would further reduce the cost while maintaining the protective efficacy of the vaccine. MDPI 2020-12-17 /pmc/articles/PMC7766959/ /pubmed/33348607 http://dx.doi.org/10.3390/vaccines8040771 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sun, Weina
McCroskery, Stephen
Liu, Wen-Chun
Leist, Sarah R.
Liu, Yonghong
Albrecht, Randy A.
Slamanig, Stefan
Oliva, Justine
Amanat, Fatima
Schäfer, Alexandra
Dinnon, Kenneth H.
Innis, Bruce L.
García-Sastre, Adolfo
Krammer, Florian
Baric, Ralph S.
Palese, Peter
A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine
title A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine
title_full A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine
title_fullStr A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine
title_full_unstemmed A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine
title_short A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine
title_sort newcastle disease virus (ndv) expressing a membrane-anchored spike as a cost-effective inactivated sars-cov-2 vaccine
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7766959/
https://www.ncbi.nlm.nih.gov/pubmed/33348607
http://dx.doi.org/10.3390/vaccines8040771
work_keys_str_mv AT sunweina anewcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine
AT mccroskerystephen anewcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine
AT liuwenchun anewcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine
AT leistsarahr anewcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine
AT liuyonghong anewcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine
AT albrechtrandya anewcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine
AT slamanigstefan anewcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine
AT olivajustine anewcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine
AT amanatfatima anewcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine
AT schaferalexandra anewcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine
AT dinnonkennethh anewcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine
AT innisbrucel anewcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine
AT garciasastreadolfo anewcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine
AT krammerflorian anewcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine
AT baricralphs anewcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine
AT palesepeter anewcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine
AT sunweina newcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine
AT mccroskerystephen newcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine
AT liuwenchun newcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine
AT leistsarahr newcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine
AT liuyonghong newcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine
AT albrechtrandya newcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine
AT slamanigstefan newcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine
AT olivajustine newcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine
AT amanatfatima newcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine
AT schaferalexandra newcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine
AT dinnonkennethh newcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine
AT innisbrucel newcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine
AT garciasastreadolfo newcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine
AT krammerflorian newcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine
AT baricralphs newcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine
AT palesepeter newcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine